Market research
For country-by-country execution pathways, start from the healthcare market research hub.
Oman
Market
AR + EN
Fieldwork
48h
to a proposal
48
countries
Context
Oman studies reflect Ministry of Health tender cycles, Directorate General of Pharmaceutical Affairs and Drug Control registration context, and public hospital formulary behaviour.
Distributor structures and interior geography influence who owns access conversations—research maps both early.
Public procurement in Oman runs through structured MOH tender cycles for many hospital-administered therapies, and missing a submission window can cost a full annual cycle of institutional volume. Research timed to support a tender needs to be scoped against that specific calendar rather than treated as a general evidence exercise.
Budget-impact and cost-effectiveness style evidence carries particular weight in Oman's public formulary conversations given fiscal pressure on health spending, so qualitative modules increasingly probe how committees weigh price against clinical benefit rather than assuming clinical superiority alone will carry a listing decision.
Oman's national health strategy has pushed for greater private-sector participation and health insurance expansion, gradually reshaping which patients access care through the traditionally dominant public MOH network versus a growing private-pay and insured segment. Research programmes should confirm current insurance and coverage status for the population being studied, since assumptions from a few years ago may no longer hold true today.
Cross-border referral for certain complex procedures exists, particularly toward UAE tertiary centres, though it is less prevalent than the medical tourism dynamics seen in the UAE itself. Where relevant to a therapy area, sizing models should account for this outbound referral rather than assuming all complex care stays within Oman.
Local distributor and marketing authorization holder relationships remain central to day-to-day commercial execution, and losing a single distributor relationship can meaningfully affect national institutional coverage given how few alternatives exist for some therapy categories. Account-level distributor health should be tracked alongside clinical adoption for any brand dependent on hospital procurement, particularly outside Muscat.
Oman combines universal coverage expansion with a growing private hospital sector in Muscat.
Specialist pools are smaller than UAE; feasibility planning is built into every proposal.
Muscat concentrates most tertiary and specialty capacity, including Royal Hospital and Sultan Qaboos University Hospital, while interior governorates rely more heavily on regional referral hospitals and primary care networks that route complex cases back to the capital. Sample plans should reflect this referral pattern rather than distributing recruitment evenly by population across the country.
A small number of distributors and marketing authorization holders manage most institutional access, concentrating commercial relationships in a way that rewards account-level intelligence for hospital-administered brands over broad-panel physician surveys.
Salalah and other secondary cities host regional hospital capacity that serves as an intermediate referral point between rural clinics and Muscat tertiary centres, and studies covering national reach should treat this tier separately from both Muscat and the smallest interior towns rather than collapsing all non-Muscat geography into one undifferentiated category.
Private hospital groups in Muscat have grown steadily, particularly in elective and specialty procedures, creating a private-pay and insured segment that behaves differently from MOH-governed public care in terms of price sensitivity and brand choice — a distinction that matters for any commercial study measuring willingness to pay.
Mandatory health insurance for expatriate workers, introduced progressively over recent years, has begun shifting some demand away from purely out-of-pocket private care toward insured private care, a transition that market sizing models should track rather than assume happened uniformly across every employer and industry sector.
Treatment algorithms and switch behaviour.
Tender and formulary objection themes.
Sequencing and account prioritization.
Oman cell with UAE/KSA harmonisation.
Extending recruitment beyond Muscat to reflect real referral and treatment patterns.
Structuring price and value evidence for MOH tender and formulary committees.
Assessing distributor coverage and account concentration risk for institutional brands nationally.
Extending fieldwork to Salalah and other regional hubs between Muscat and interior towns.
Understanding adoption and price sensitivity among Muscat's growing private-pay and insured population.
Targeted specialist outreach for dialysis, transplant, and chronic kidney disease categories nationally.
Understanding public and private uptake pathways for immunization and infectious disease therapies.
Hybrid quant–qual designs with Arabic–English field teams and documented recruitment QC.
Feasibility is checked before any quantitative sample is committed, since several specialties outside Muscat rely on a very small number of treating physicians; where that pool is too thin, we recommend a qualitative-led design instead.
Recruitment lists are validated against hospital rosters and professional society membership rather than relying solely on distributor-supplied contacts, which can skew toward existing customers and understate the true addressable population.
Where a study spans Muscat and interior governorates, we document any geography-driven differences explicitly rather than blending them into a single national figure that would mask real access gaps.
Bilingual field teams handle both Arabic and English materials, and screener language is reviewed with local advisors to ensure medical terminology reads naturally to Omani physicians and pharmacists rather than as a direct translation from an English-only original.
Pilot interviews with two or three well-placed specialists typically precede a full quantitative launch for any therapy with limited treating physicians, catching terminology, framing, or logistics issues before they affect a larger sample.
Every deliverable is checked against the original decision statement before it is finalized, and any secondary theme that does not change the sponsor's action is documented as context rather than dressed up as a strategic recommendation. This discipline keeps reports short enough for busy stakeholders to actually read and use.
Diabetes, oncology, and cardiovascular programs are common in Oman. Diabetes in particular carries a heavy disease burden nationally, keeping demand for cardiometabolic research consistently strong, while oncology and rare disease work typically routes through Royal Hospital or Sultan Qaboos University Hospital given their tertiary referral role. Renal care also carries above-average research demand given the prevalence of chronic kidney disease linked to the broader diabetes burden, and dialysis and transplant services are concentrated in a small number of specialist centres nationally, making named-expert recruitment the practical approach.
Decision and stakeholder workshop.
Field with geography-aware sampling.
Readout mapped to launch or access owners.
Early confirmation of specialist availability in Muscat and interior governorates before scaling quantitative fieldwork nationally.
Optional module timing evidence delivery against MOH tender submission windows and documentation deadlines.
Scheduled follow-up waves for sponsors defending access against a new competitor or facing formulary re-review.
Optional assessment of distributor account concentration and service level for institutional brands dependent on hospital procurement across regions.
Oman rewards early feasibility in specialist recruitment. Interior governorate scarcity in particular means a study designed around Muscat-only assumptions can badly misjudge national reach, especially for specialties concentrated in one or two tertiary centres serving the whole country.
Thin cells are flagged before sponsors commit to oversized quant. Sponsors who confirm feasibility by governorate before fielding avoid discovering mid-study that an interior region simply cannot support the planned sample size, saving both budget and timeline in the process.
Pair this page with the Oman pharma company directory for full-funnel planning. Confirm whether Muscat, interior governorates, or both are in scope before instruments are finalized, align on which MOH tender calendar the evidence needs to support, and name the internal stakeholder who will act on the findings once delivered.
Physician surveys, payer and access qual, stakeholder mapping, and executive synthesis aligned to MOH tender and formulary behaviour.
Muscat concentration versus interior referral patterns requires segmented design so forecasts reflect real patient flows.
Yes. Harmonised GCC modules preserve Oman-specific MOH context while enabling regional portfolio reads.
Programs map Royal Hospital, SQUH, and relevant private groups depending on therapy and access objective.
See the pharmaceutical companies in Oman page linked below for BOFU company-intent research.
This directorate governs drug registration, pharmacovigilance, and pricing approval in Oman, and its timelines can move independently of Saudi SFDA or UAE MOHAP processes even for the same molecule. Research programmes track Oman-specific registration status separately rather than assuming Gulf-wide approval implies local listing readiness, since a molecule registered elsewhere in the Gulf may still be pending locally.
Specialist care outside Muscat is often delivered through regional referral hospitals with smaller teams and longer patient catchment areas, which means recruitment in the interior typically takes longer per completed interview than in the capital. We build this into field timelines rather than applying a flat national recruitment rate that assumes Muscat-level responsiveness everywhere.
Yes, where access can be arranged and is appropriate to the study scope. These tertiary referral centres treat a disproportionate share of complex and specialty cases nationally, so they are often the right starting point for oncology, rare disease, or advanced therapy research even when the broader study also covers regional facilities, and their specialists are frequently the most credible voices for advisory-style qualitative work.
Oman's public spending constraints have historically made price and budget-impact evidence more central to formulary decisions than in wealthier neighbouring markets, and that sensitivity has increased further as the government has pursued fiscal diversification under its Vision 2040 economic plan. Research programmes should expect budget-holder objections to carry real weight rather than treating them as a formality.
Yes, where the therapy area and decision warrant it. Salalah and other regional hubs sit between Muscat tertiary care and the smallest interior towns in terms of specialist density, so we scope them as a distinct field cell rather than lumping them in with either extreme, which keeps regional readiness assessments realistic and defensible when presented to leadership.
We typically run a short round of pilot outreach — two or three specialists per relevant region — to confirm realistic recruitment numbers before finalizing sample size and budget. This catches scarcity issues early rather than mid-field, when a redesign becomes far more expensive and can delay the entire delivery timeline.
Yes. The same underlying stakeholder map and instrument design can be adapted for an initial launch-readiness study and later reused, with updates, for an access defense against a new competitor or a formulary re-review, which keeps findings comparable over time and reduces both the cost and turnaround time of the second engagement considerably.
Name the brand, the country, and the breakdown your syndicated feed cannot give you. We send a project- and country-priced proposal — typically within 48 hours.
US No. +1 888 465 5557Europe No. +44 7727 666682Middle East, Africa and Asia No. +20 120 688 2323